Dark

Check out our API

ADMS
Adamas Pharmaceuticals, Inc.
stock NASDAQ

Inactive

Nov 23, 2021

8.22USD+0.735%(+0.06)3,151,400

Pre-market

0.00USD-100.000%(-8.16)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Nov 24, 2021

09:13AM EST Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). GlobeNewswire Inc

Nov 23, 2021

08:00AM EST Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) expired at 11:59 p.m. on November 22, 2021. GlobeNewswire Inc

Nov 17, 2021

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021 Benzinga

07:41AM EST Northland Capital Markets Downgrades Adamas Pharmaceuticals to Market Perform, Announces $8.5 Price Target Benzinga

Nov 2, 2021

06:30PM EDT LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. - ADMS PR Newswire

Oct 19, 2021

04:29PM EDT Adamas Pharmaceuticals Shares Move Higher; Magnetar Financial Reports In 13D Filing A 6.85% Stake In Co Benzinga

Oct 12, 2021

12:20PM EDT ADAMAS PHARMACEUTICALS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. - ADMS Business Wire

10:48AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021 Benzinga

06:52AM EDT JMP Securities Downgrades Adamas Pharmaceuticals to Market Perform Benzinga

06:48AM EDT Piper Sandler Downgrades Adamas Pharmaceuticals to Neutral, Raises Price Target to $8 Benzinga

06:40AM EDT HC Wainwright & Co. Downgrades Adamas Pharmaceuticals to Neutral, Lowers Price Target to $9.1 Benzinga

Oct 11, 2021

03:17PM EDT Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher Benzinga

12:13PM EDT Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals Benzinga

11:44AM EDT William Blair Downgrades Adamas Pharmaceuticals to Market Perform Benzinga

06:36AM EDT Supernus To Acquire Adamas Through Tender Offer For $8.10/Shr Cash RTTNews

06:32AM EDT Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals For $8.10/Share Or An Aggregate Of ~$400M Benzinga

06:30AM EDT Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals GlobeNewswire Inc

Oct 8, 2021

04:15PM EDT Adamas Announces New Employment Inducement Grants Business Wire

Oct 1, 2021

09:15AM EDT Adamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health Awards Business Wire

Sep 16, 2021

09:23AM EDT Adamas Announces GOCOVRI Presentations At International Parkinson And Movement Disorder Society's Congress RTTNews

09:20AM EDT Adamas Announces GOCOVRI Presentations At Upcoming International Parkinson And Movement Disorder Society's Congress Sept. 17-22 Benzinga

09:15AM EDT Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society's (MDS) Congress Business Wire

Sep 10, 2021

07:36PM EDT Looking Into Adamas Pharmaceuticals's Return On Capital Employed Benzinga

05:00PM EDT Adamas Announces New Employment Inducement Grants Business Wire

Aug 30, 2021

04:11PM EDT Adamas to Present at Upcoming September Investor Conferences Business Wire

Aug 13, 2021

04:16PM EDT Adamas Announces New Employment Inducement Grant Business Wire

Aug 9, 2021

04:14PM EDT Adamas Pharmaceuticals Q2 EPS $(0.27) Beats $(0.29) Estimate, Sales $22.00M Beat $21.95M Estimate Benzinga

04:01PM EDT Adamas Reports Second Quarter 2021 Financial Results Business Wire

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 2, 2021

04:02PM EDT Adamas to Announce Second Quarter Financial Results and Host Conference Call on August 9, 2021 Business Wire

Jul 22, 2021

09:19AM EDT Adamas Pharma Announces Issuance Of New Patents For GOCOVRI And ADS-4101 RTTNews

09:16AM EDT Adamas Announces Issuance Of New Patents For GOCOVRI And ADS-4101 Benzinga

Jul 9, 2021

04:05PM EDT Adamas Announces New Employment Inducement Grant Business Wire

Jul 8, 2021

04:02PM EDT Adamas to Present at Upcoming William Blair Biotech Focus Conference Business Wire

Jun 23, 2021

04:42PM EDT Adamas to Present at Upcoming SVB Leerink CNS Forum Business Wire

Jun 22, 2021

10:22AM EDT Return On Capital Employed Overview: Adamas Pharmaceuticals Benzinga

Jun 11, 2021

04:08PM EDT Adamas Announces New Employment Inducement Grant Business Wire

Jun 10, 2021

09:40AM EDT Adamas : Data Analysis Supports GOCOVRI As Treatment For Motor Complications For People With Parkinson's Disease RTTNews

09:16AM EDT Adamas Pharma Highlights New Data Analysis Supporting GOCOVRI As Treatment For Motor Complications For People With Parkinson's Disease Benzinga

09:15AM EDT New Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson's Disease Business Wire

Jun 7, 2021

06:17AM EDT HC Wainwright & Co. Maintains Buy on Adamas Pharmaceuticals, Lowers Price Target to $10 Benzinga

Jun 4, 2021

10:52AM EDT Adamas Pharmaceuticals: Return On Capital Employed Insights Benzinga

May 27, 2021

04:11PM EDT Adamas to Present at Upcoming June Conferences Business Wire

May 10, 2021

04:28PM EDT Adamas Pharmaceuticals Q1 EPS $(0.36) Beats $(0.51) Estimate, Sales $19.30M Miss $20.02M Estimate Benzinga

04:07PM EDT Adamas Reports Q1 Loss Per Share Of $0.36 Vs. $0.59 Per Share Last Year RTTNews

04:02PM EDT Adamas Reports First Quarter 2021 Financial Results Business Wire

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

May 7, 2021

04:05PM EDT Adamas Announces New Employment Inducement Grant Business Wire

Apr 29, 2021

04:04PM EDT Adamas to Present at Upcoming BofA Conference Business Wire

Apr 27, 2021

10:37AM EDT Adamas Pharmaceuticals Granted U.S. Patent Titled 'Methods and compositions for the treatment of seizure-related disorders' Benzinga

09:15AM EDT Adamas Launches "Picture More Time" Campaign to Raise Awareness and Understanding of the Impact of OFF Time and Dyskinesia for People With Parkinson's Disease and Care Partners Business Wire

Apr 26, 2021

04:04PM EDT Adamas to Announce First Quarter Financial Results and Host Conference Call on May 10, 2021 Business Wire

Apr 19, 2021

09:15AM EDT Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinson's disease presented at American Academy of Neurology (AAN) Annual Meeting Business Wire

Apr 15, 2021

09:17AM EDT Adamas To Present Two Posters At American Academy Of Neurology 73rd Annual Meeting Benzinga

09:15AM EDT Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting Business Wire

Apr 13, 2021

09:48AM EDT Adamas Pharmaceuticals Shares See Volume; Co Granted U.S. Patent Titled 'Methods and compositions for the treatment of seizure-related disorders' Benzinga

Apr 7, 2021

05:19PM EDT Adamas to Present at Upcoming Needham Conference Business Wire

Mar 29, 2021

03:12PM EDT Adamas' Gocovri Treatment Doubles ON Time Without Dyskinesia In Parkinson's disease, New Analysis Shows Benzinga

09:18AM EDT Adamas Highlights Publication Of Article In Frontiers In Neurology Journal Titled 'Amantadine ER (Gocovri) significantly increases ON time without any dyskinesia: Pooled analyses from pivotal studies in Parkinson's disease' Benzinga

09:15AM EDT Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskinesia in patients with Parkinson's disease Business Wire

Mar 17, 2021

07:43AM EDT The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes Benzinga

Mar 5, 2021

04:02PM EST Adamas Announces New Employment Inducement Grant Business Wire

Mar 1, 2021

04:04PM EST Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Business Wire

Feb 25, 2021

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

Feb 24, 2021

10:37PM EST Adamas Pharma Announces Pricing Of Follow-on Public Offering Of 12.50 Mln At $4.40/shr RTTNews

09:16PM EST Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offering Business Wire

04:09PM EST Adamas Pharma Reports Launch Of Follow-On Offering Of Common Stock, No Size Disclosed Benzinga

04:08PM EST Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering Business Wire

Feb 23, 2021

04:44PM EST Adamas Pharmaceuticals: Q4 Earnings Insights Benzinga

04:08PM EST Adamas Pharmaceuticals Sees FY 2021 Total Operating Expenses Expenses $115M-$130M Benzinga

04:06PM EST Adamas Pharmaceuticals Q4 EPS $(0.64) Misses $(0.51) Estimate, Sales $21.00M Beat $20.96M Estimate Benzinga

04:03PM EST Adamas Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

04:09AM EST Earnings Scheduled For February 23, 2021 Benzinga

Feb 22, 2021

10:28AM EST A Preview Of Adamas Pharmaceuticals's Earnings Benzinga

Feb 17, 2021

04:07PM EST Adamas to Present at Upcoming Healthcare Conferences Business Wire

Feb 10, 2021

09:24AM EST Adamas to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call on February 23, 2021 Business Wire

Feb 2, 2021

08:05AM EST The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment Benzinga

Feb 1, 2021

02:21PM EST Adamas Pharma Shares To Resume Trade At 2:35 p.m. EST Benzinga

02:07PM EST Adamas Announces FDA Approval for Second Indication for GOCOVRI(r) as an Adjunctive Treatment to levodopa/carbidopa in Parkinson's Disease Patients Experiencing OFF Episodes Business Wire

01:01PM EST Adamas Pharma Shares Halted News Pending Benzinga

08:12AM EST Adamas Announces Settlement Of Patent Litigation With Zydusa Benzinga

08:07AM EST Adamas Enters Settlement Of Patent Litigation With Zydus RTTNews

08:01AM EST Adamas Announces Settlement of Patent Litigation with Zydus Business Wire

Jan 31, 2021

05:22AM EST Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates Benzinga

Jan 30, 2021

01:19PM EST The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More Benzinga

Jan 13, 2021

09:15AM EST Adamas Sees Q4 Sales $20.8M vs $21.7M Estimate; FY20 Sales $74.2M vs $75M Est. Benzinga

09:15AM EST -- Total revenues expected to be $20.8 million for fourth quarter 2020and $74.2 million for full year 2020 -- GlobeNewswire Inc

Jan 7, 2021

06:03PM EST Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the ICR Conference 2021, being held January 11-14, 2021. GlobeNewswire Inc

Jan 5, 2021

09:15AM EST Adamas Completes Acquisition of OSMOLEX ER GlobeNewswire Inc

Jan 4, 2021

04:15PM EST Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Companys Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright VIRTUAL BioConnect Conference, being held January 11 14, 2021. GlobeNewswire Inc

Dec 11, 2020

04:02PM EST Adamas Announces New Employment Inducement Grant GlobeNewswire Inc

Dec 2, 2020

07:04AM EST Osmotica Pharmaceuticals plc Announces Agreement to Settle Patent Litigation with Adamas; Adamas Will Acquire Global Rights To OSMOLEX ER $7.5M Benzinga

06:52AM EST Adamas Signs Agreement To Settle Its Ongoing Patent Litigation With Osmotica RTTNews

06:51AM EST Adamas Announces Agreement to Amend Royalty-Backed Loan Agreement GlobeNewswire Inc

06:50AM EST Adamas Announces Agreement to Settle Patent Litigation with Osmotica GlobeNewswire Inc

Nov 24, 2020

04:03PM EST Adamas to Present at Upcoming Evercore ISI Conference GlobeNewswire Inc

Nov 23, 2020

09:15AM EST Adamas announces changes to its Board of Directors with the GlobeNewswire Inc

Nov 18, 2020

04:02PM EST Adamas to Present at Upcoming Piper Sandler Conference GlobeNewswire Inc

Nov 13, 2020

04:05PM EST Adamas Announces New Employment Inducement Grant GlobeNewswire Inc

Nov 5, 2020

04:20PM EST Adamas Pharmaceuticals Narrows FY20 R&D Expenses From $8M-$12M To $9M-$11M, SG&A Expenses $113M-$127M To $100M-$121M Benzinga

04:18PM EST Adamas Pharmaceuticals Q3 EPS $(0.42) Beats $(0.48) Estimate, Sales $20.20M Miss $20.95M Estimate Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

09:26AM EST Adamas Pharma Reports $7.5M Settlement Deal For Previously-Disclosed Securities Class-Action Suits, Plymouth v. Adamas Benzinga

09:25AM EST Adamas announces settlement agreement of previously disclosed GlobeNewswire Inc

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 26, 2020

04:04PM EDT Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 third quarter financial results on Thursday, November 5, 2020, after market close. Subsequently, Adamas management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update. GlobeNewswire Inc

Oct 9, 2020

04:03PM EDT Adamas Announces New Employment Inducement Grant GlobeNewswire Inc

Oct 1, 2020

09:43AM EDT Adamas Appoints Adrian Quartel As New Chef Medical Officer Benzinga

09:15AM EDT Adamas appoints new Chief Medical Officer, Adrian Quartel, MD GlobeNewswire Inc

Sep 11, 2020

04:04PM EDT Adamas Announces New Employment Inducement Grant GlobeNewswire Inc

09:34AM EDT Adamas Presents New Post-hoc Data Analysis For GOCOVRI In Parkinson's Disease Patients With Dyskinesia RTTNews

09:17AM EDT Adams Pharma Highlights Presentation Of Post-Hoc Data Analysis For GOCOVRI In Parkinson's Disease Patients With Dyskinesia At 2020 Movement Disorder Society Virtual Congress Benzinga

09:15AM EDT Adamas presents new post-hoc data analysis for GOCOVRI GlobeNewswire Inc

Sep 8, 2020

04:05PM EDT Adamas to Present at Upcoming HC Wainwright Conference GlobeNewswire Inc

Sep 1, 2020

09:15AM EDT Adamas Appoints Anna Richo to Board of Directors GlobeNewswire Inc

Aug 14, 2020

04:04PM EDT Adamas Announces New Employment Inducement Grant GlobeNewswire Inc

Aug 6, 2020

04:27PM EDT Adamas Pharmaceuticals Q2 EPS $(0.37) Beats $(0.61) Estimate, Sales $18.79M Beat $15.32M Estimate Benzinga

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

07:19AM EDT Biocryst Pharmaceuticals Q2 EPS $(0.24) Beats $(0.25) Estimate Benzinga

Jul 23, 2020

04:02PM EDT Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 second quarter financial results on Thursday, August 6, 2020, after market close. Subsequently, Adamas management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update. GlobeNewswire Inc

Jul 15, 2020

08:03AM EDT Adamas Highlights Presentation Of New Post-Hoc Phase 3 Data Analysis For GOCOVRI Ini Parkinson's Disease At 2020 American Academy Of Neurology (AAN) Science Highlights Platform Benzinga

08:00AM EDT Adamas presents new post-hoc Phase 3 data analysis for GlobeNewswire Inc

Share